Pharmacy Benefits Management Services Home

The 2012 Chest Guidelines provide a weak recommendation (Grade 2C) favoring the use of VKA and LMWH over the newer oral anticoagulants (dabigatran and rivaroxaban) due to the lack of post-marketing safety data.4 Further study is needed for patient populations not represented or under-represented in EINSTEIN including patients with cancer ... ................
................